IL22 and autoimmune polyendocrine syndrome type 1: Hence, Kisand et al. found neutralizing antibodies to IL-22 in APS-1 patients with CMC (in 91% of cases), while these antibodies were not identified in patients with CMC without a mutation in the AIRE gene, isolated hypoparathyroidism, isolated AD, APS-2, psoriasis, rheumatoid arthritis and other autoimmune diseases [6].